Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.30 USD
-0.01 (-2.17%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.30 0.00 (-0.66%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CARA 0.30 -0.01(-2.17%)
Will CARA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CARA
TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
CARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
Other News for CARA
Bullish Wednesday For Marijuana Stocks - Australis Capital, Leafbuyer Techs Among Top Gainers
Bearish Sentiment Across The Cannabis Space - Check Full Movers For September 12, 2024
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 26, 2024
CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q2 2024
Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more